Acronym BluePharmTrain
Category
Marine Biotechnology
Title A multi-disciplinary blue biotechnology research & training network Programme FP7
Instrument (FP6)
Contact Type (FP7)
Strand (Interreg)
FP7 - Networks for Initial Training (ITN)
Theme (FP7)
Activity Area (FP6)
Regional Area (Interreg)
Action (COST)
PEOPLE – Marie Curie Actions
Specific Programme (FP7)
People
Funding source European Coordinator Detmer Sipkema Coordinator email detmer.sipkema@wur.nl
Coordinator institution
WUR - Wageningen University and Research (Netherlands)
Institutions involved
NA - Cardiff University (United Kingdom) ,
DSMZ - Leibniz Institut DSMZ-German Collection of Microorganims and Cell Cultures GmbH (Germany) ,
MATIS - Matis Ltd (Iceland) ,
NA - Pharma Mar SA (Spain) ,
CSIC - Spanish National Research Council (Spain) ,
ETH Zurich - Swiss Federal Institute of Technology Zurich (Switzerland) ,
TALTECH - Tallinn University of Technology (Estonia) ,
UCC - University College Cork (Ireland) ,
RuG - University of Groningen (Netherlands) ,
HI - University of Iceland (Iceland) ,
Start year 2013 End year 2017 Funding (€) € 3,896,333 Website https://cordis.europa.eu/project/id/607786/it Summary BLUEPHARMTRAIN is a multi -disciplinary alliance of 20 academic and industrial partners that will excel in research and training through integration of complementary expertise in cell biology, microbiology, natural product chemistry, genomics & transcriptomics (omics) and socio - economics. We will adopt cutting - edge omics technologies to give a new boost to the more traditional disciplines: microbial isolation, cell culture and natural product chemistry to go beyond the current scientific frontiers. For example, metagenomic and transcriptomic data will be applied to identify the metabolic potential and restrictions of - yet - uncultured microbes and will serve for the design of tailor - made cultivation conditions. In additio n, heterologous expression of bioactive gene clusters and enzymes able to perform unusual modifications will serve as an alternative strategy to unlock the bioactive potential of sponges. Thus we aim to develop an extensive technology platform that is appl icable for obtaining a wide variety of bioactive compounds from distinct sponges and their microbes. BLUEPHARMTRAIN will provide a complementary set of experimental and conceptual local and network - wide training modules and workshops to 15 young researchers. The recruited fellows will work towards personalized training plans to meet individual needs and interests, generating a critical mass of young researchers in the emerging field of blue biotechnology. The presence of a large consortium of vers atile biotechnology, pharmaceutical and consultancy firms ensures a good balance between academic and transferable skills acquired by the fellows
Keywords
Microbiome;
Human health;
Bioactive compounds;
Sponge;
Metagenomic;
Drug discovery;
Bioprospecting;
Genomic;
Marine Region
76
Not associated to marine areas
0
Marine Region Map
